NCIt definition : A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related
apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity.
Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating
signal transduction pathways that may result in tumor cell apoptosis and a reduction
in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2,
also known as DR5 (death receptor 5), is expressed on the surfaces of many types of
malignant cells.;
UNII : 237GB6IDKO;
CAS number : 918127-53-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 918127-53-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;